KYMR
Kymera Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +5.7% ·
net new positions +8.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 3.10K | $81,538 | +1 | −1 |
| Q2 2026 | 101 | +13 | 52.72M | $6.01B | +15 | −2 |
| Q1 2026 | 91 | -4 | 48.20M | $4.01B | +6 | −11 |
| Q4 2025 | 94 | 0 | 48.74M | $3.79B | +1 | n/a |
| Q3 2025 | 17 | 0 | 32.08M | $1.82B | n/a | −1 |
| Q2 2025 | 15 | +3 | 31.72M | $1.38B | +3 | n/a |
| Q1 2025 | 9 | -3 | 16.51M | $451.78M | n/a | −3 |
| Q4 2024 | 12 | +1 | 15.63M | $628.72M | +1 | n/a |
| Q3 2024 | 10 | 0 | 13.10M | $619.83M | +1 | −1 |
| Q2 2024 | 10 | n/a | 13.21M | $394.27M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.87M | +3.4% | $276.39M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 2 | Wellington Management ✦ | 5.31M | +14.9% | $213.51M | 0.0% | ▲ Add | 3 | SEC ↗ ×7 |
| 3 | State Street Global Advisors ✦ (passive) | 1.69M | n/a | $67.94M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.11M | +5.0% | $44.48M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 173.75K | -35.7% | $6.99M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Soros Fund Management ✦ | 120.37K | New | $4.84M | 0.1% | New | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 115.92K | +205.0% | $4.66M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 91.23K | 0.0% | $3.67M | 0.0% | Held | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 82.58K | -56.1% | $3.32M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 58.57K | -4.5% | $2.36M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 6.83K | -94.2% | $274,972 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 6.58K | -46.4% | $264,552 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Soros Fund Management | $4.84M | 0.1% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 254 holders, 96.17M shares, $7.04B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 262 sh · $30,423
Officer, Director · 4.88K sh · $552,158
Officer, Director · 7.60K sh · $869,782
Officer, Director · 8.23K sh · $949,742
Officer, Director · 3.52K sh · $392,826
Officer, Director · 5.51K sh · $618,985
Officer · 3.02K sh · $353,350
Officer · 2.14K sh · $251,247
Officer · 1.21K sh · $139,700
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
3.3% of class · View original SEC filing ↗